BRAF exon 15 and NRAS exon 1 and 2 were investigated by Sanger sequencing of formalin fixed paraffin embedded (FFPE) primary tumors from time of diagnosis, and metastatic tumors collected before inclusion in the clinical trial (Table 2). Here, NRAS is linked to metastatic neoplasm.